ArticleSovremennye tekhnologii v meditsine2025
The Development of Inner Ear Membrane Analog for Experimental Otorhinolaryngology.
Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological part of the study: Several substrate options were tested to create the mRWM, including 2 variants of Viscoll collagen membranes (IMTEK, Russia) and a multi-component G-Derm membrane (G-DERM, Russia). In the first variant, only HaCaT epithelial cells were seeded on the membranes, and in the second variant, primary human dermal fibroblasts were seeded together with HaCaT epithelial cells (sequential application). The obtained mRWM were evaluated by morphological criteria using histochemical methods. As a result, the decision was made to use mRWM constructed on Viscoll membranes with the inclusion of both primary fibroblasts and human epithelial cells. Technical part of the study: A series of scientific experiments has been performed on the obtained mRWM aimed at studying the permeability and developing modes of electrophysical action on this biological barrier while maintaining its morphological and functional integrity and ensuring accelerated passage of dexamethasone through it. To accelerate the passage of dexamethasone across the mRWM, the electrophysical system initiated targeted iontophoresis of negatively charged dexamethasone molecules in parallel with electroporation of cell membranes in the sample. After the exposure, the residual viability of mRWM was assessed by histochemical staining with calcein and propidium iodide. The change in dexamethasone concentration after passage across the mRWM was assessed using a highly sensitive chromatograph. Conclusion: During the optimization of the mRWM fabrication protocol and the selection of suitable substrate components and cellular material, the model based on a thin Viscoll collagen membrane has been chosen as a substrate and primary human dermal fibroblasts and epithelial cells of the HaCaT line as a cellular material. The obtained experimental samples of mRWM represent a semipermeable membrane with living cells on the surface and are an alternative analog of the native structure, reproducing its geometric and morphofunctional characteristics. In addition, there has been demonstrated a method of using the for preclinical studies of electrophysical devices designed for accelerated passage of target substances through this membrane using electroporative and iontophoretic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.